Abstract
The hERG channel plays an important role in the repolarization phase of the cardiac action potential. Blockage of the channel conductance can lead to prolongation of the cardiac action potential and the QT interval on the surface electrocardiogram, which may result in deadly arrhythmias. hERG channel blockade is a leading cause for drug withdrawal from the drug development pipeline or marketplace. However, not all hERG-blocking and QT-prolonging drugs cause arrhythmia. Therefore, understanding the molecular mechanisms of drug interactions with the hERG channel and the subsequent modulation of the channel gating leading to different pro-arrhythmia outcomes is crucial for drug design and development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
